Form 8-K TANDEM DIABETES CARE For: Nov 06
�
�
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
�
FORM 8-K
�
CURRENT REPORT
Pursuant to Section�13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2014
�
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
�
�
|
Delaware |
� |
001-36189 |
� |
20-4327508 |
|
(State or other jurisdiction of incorporation) |
� |
(Commission File Number) |
� |
(I.R.S. Employer |
�
|
11045 Roselle Street, San Diego, CA |
� |
92121 |
|
(Address of principal executive offices) |
� |
(Zip Code) |
Registrants telephone number, including area code: (858)�366-6900
N/A
(Former name or former address, if changed since last report)
�
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
� |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
� |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
� |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
� |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
�
�
�
�
�
Item�2.02 Results of Operations and Financial Condition.
On November 6, 2014, we issued a press release announcing our financial results for the quarter ended September 30, 2014. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information under this Item�2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed filed for the purposes of Section�18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
�
�
Item�9.01 Financial Statements and Exhibits.
(d) Exhibits.
�
|
Number |
�� |
Description |
|
� |
� |
� |
|
99.1 |
�� |
Press release of Tandem Diabetes Care, Inc. dated November 6, 2014. |
�
�
�
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
|
� |
�� |
Tandem Diabetes Care, Inc. |
|
� |
� |
|
|
Date: November 6, 2014 |
�� |
/s/ David B. Berger� |
|
� |
�� |
David B. Berger |
|
� |
�� |
General Counsel |
�
�
�
INDEX TO EXHIBITS
�
|
Number |
�� |
Description |
|
� |
� |
� |
|
99.1 |
�� |
Press release of Tandem Diabetes Care, Inc. dated November 6, 2014. |
�
Exhibit 99.1
FOR IMMEDIATE RELEASE
Tandem Diabetes Care Reports Third Quarter 2014 Financial Results
San Diego, November 6, 2014 �Tandem Diabetes Care�, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim� Insulin Pump, today reported its financial results for the quarter ended September 30, 2014.
�
In comparing the third quarter of 2014 to the same period of 2013:
|
� |
Sales grew 74 percent to $13.5 million from $7.8 million |
|
� |
t:slim Pump shipments grew 59 percent to 2,935 pumps from 1,851 pumps |
In comparing the nine months ended September 30, 2014 to the same period of 2013:
|
� |
Sales grew 70 percent to $31.8 million from $18.8 million, which included $1.9 million of t:slim Pump sales recognized in the first quarter of 2013 that were shipped in the fourth quarter of 2012 |
|
� |
t:slim Pump shipments grew 70 percent to 6,893 pumps from 4,066 pumps |
Our strong growth continued in the third quarter, as more people than ever before chose the t:slim Pump for their insulin therapy management, said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. We also made significant R&D progress over the past several months, highlighted by the recent 510(k) submission of our t:flex" Insulin Pump.��Together with our PMA application for the t:slim G4" Insulin Pump, we now have two new products under FDA review that have the potential to expand our product portfolio and further serve the needs of the diabetes community.
�
Gross margin was 33 percent for both the quarter ended September 30, 2014 and the same period of 2013.
�
For the third quarter of 2014, operating expenses totaled $23.4 million compared to $14.7 million for the same period of 2013.��The increase in operating expenses is primarily associated with the expansion of commercial operations and non-cash, stock-based compensation.
�
Operating loss for the third quarter of 2014 was $19.0 million, compared to $12.1 million for the same period of 2013.��This included non-cash, stock-based compensation of $3.7 million for the quarter ended September 30, 2014 compared to $1.0 million for the comparable period of 2013.
�
As of September 30, 2014, the Company had $81.9 million in cash, cash equivalents and short-term investments.
�
For the year ending December 31, 2014, the Company is updating its guidance as follows:
|
� |
Sales are estimated to be in the range of $48.0 million to $50.0 million, and |
|
� |
Operating margin is estimated to be in the range of negative 150 percent to 160 percent, which includes approximately $15.0 million to $16.0 million in non-cash, stock-based compensation expense. |
�
Conference Call
The Company will hold a conference call and simultaneous webcast today at 11:00am Eastern Time (8:00am Pacific Time).��The link to the webcast will be available by accessing the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days.��To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code "15463574".
�
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.
�
t:slim and Tandem Diabetes Care are registered trademarks, and t:flex and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
�
Follow Tandem Diabetes Care:
Twitter @tandemdiabetes, use #tslim, #tconnect and $TNDM.
Facebook at www.facebook.com/TandemDiabetes
LinkedIn at www.linkedin.com/in/TandemDiabetes
�
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section�27A of the Securities Act of 1933, as amended, and Section�21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements.�These forward-looking statements relate to the Companys projected financial results, the Companys ability to further drive adoption of the t:slim� Insulin Pump in the insulin dependent diabetes market, and the Companys ability to gain FDA approval and commercially launch both the t:flex Insulin Pump and t:slim G4 Insulin Delivery System. The Companys actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the Companys products may be negatively impacted by lack of market acceptance by physicians and people with diabetes. Other risks and uncertainties include the Companys inability to manufacture products in commercial quantities at an acceptable cost and in accordance with quality requirements; the Companys inability to contract with additional third-party payors for reimbursement of the Companys products; possible delays in the Companys product development programs; possible future actions of the U.S. Food and Drug Administration or any other regulatory body or governmental authority; and other risks identified in the Companys most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.��
�
# # #
�
�
�
TANDEM DIABETES CARE, INC.
CONDENSED BALANCE SHEETS
(in thousands)
�
|
� |
� |
September 30, |
� |
� |
December 31, |
� |
||
|
� |
� |
2014 |
� |
� |
2013 |
� |
||
|
� |
� |
(Unaudited) |
� |
� |
� |
� |
� |
|
|
Assets |
� |
� |
� |
� |
� |
� |
� |
� |
|
Current assets: |
� |
� |
� |
� |
� |
� |
� |
� |
|
Cash and cash equivalents and short-term investments |
� |
$ |
79,877 |
� |
� |
$ |
129,480 |
� |
|
Restricted cash |
� |
� |
2,000 |
� |
� |
� |
2,050 |
� |
|
Accounts receivable, net |
� |
� |
5,843 |
� |
� |
� |
5,299 |
� |
|
Inventory |
� |
� |
11,892 |
� |
� |
� |
10,330 |
� |
|
Other current assets |
� |
� |
1,438 |
� |
� |
� |
1,830 |
� |
|
Total current assets |
� |
� |
101,050 |
� |
� |
� |
148,989 |
� |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Property and equipment, net |
� |
� |
12,345 |
� |
� |
� |
9,886 |
� |
|
Other long term assets |
� |
� |
3,170 |
� |
� |
� |
3,340 |
� |
|
Total assets |
� |
$ |
116,565 |
� |
� |
$ |
162,215 |
� |
|
Liabilities and stockholders equity |
� |
� |
� |
� |
� |
� |
� |
� |
|
Current liabilities: |
� |
� |
� |
� |
� |
� |
� |
� |
|
Accounts payable, accrued expense and employee-related liabilities |
� |
$ |
12,605 |
� |
� |
$ |
10,102 |
� |
|
Deferred revenue |
� |
� |
638 |
� |
� |
� |
411 |
� |
|
Other current liabilities |
� |
� |
2,413 |
� |
� |
� |
4,086 |
� |
|
Total current liabilities |
� |
� |
15,656 |
� |
� |
� |
14,599 |
� |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Notes payablelong-term |
� |
� |
29,416 |
� |
� |
� |
29,397 |
� |
|
Other long-term liabilities |
� |
� |
4,010 |
� |
� |
� |
2,682 |
� |
|
Total liabilities |
� |
� |
49,082 |
� |
� |
� |
46,678 |
� |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Total stockholders equity |
� |
� |
67,483 |
� |
� |
� |
115,537 |
� |
|
Total liabilities and stockholders equity |
� |
$ |
116,565 |
� |
� |
$ |
162,215 |
� |
�
�
�
�
�
TANDEM DIABETES CARE, INC.
CONDENSED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands except per share data)
�
|
� |
� |
Three Months Ended |
� |
� |
Nine Months Ended |
� |
||||||||||
|
� |
� |
September 30, |
� |
� |
September 30, |
� |
||||||||||
|
� |
� |
2014 |
� |
� |
2013 |
� |
� |
2014 |
� |
� |
2013 |
� |
||||
|
Sales |
� |
$ |
13,514 |
� |
� |
$ |
7,776 |
� |
� |
$ |
31,834 |
� |
� |
$ |
18,762 |
� |
|
Cost of sales |
� |
� |
9,117 |
� |
� |
� |
5,243 |
� |
� |
� |
23,121 |
� |
� |
� |
13,783 |
� |
|
Gross profit |
� |
� |
4,397 |
� |
� |
� |
2,533 |
� |
� |
� |
8,713 |
� |
� |
� |
4,979 |
� |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Operating expenses: |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Selling, general and administrative |
� |
� |
18,895 |
� |
� |
� |
12,009 |
� |
� |
� |
55,004 |
� |
� |
� |
30,217 |
� |
|
Research and development |
� |
� |
4,508 |
� |
� |
� |
2,652 |
� |
� |
� |
11,870 |
� |
� |
� |
7,733 |
� |
|
Total operating expenses |
� |
� |
23,403 |
� |
� |
� |
14,661 |
� |
� |
� |
66,874 |
� |
� |
� |
37,950 |
� |
|
Operating loss |
� |
� |
(19,006 |
) |
� |
� |
(12,128 |
) |
� |
� |
(58,161 |
) |
� |
� |
(32,971 |
) |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Other income (expense), net |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Other expense, net |
� |
� |
(893 |
) |
� |
� |
(1,206 |
) |
� |
� |
(2,897 |
) |
� |
� |
(3,542 |
) |
|
Change in fair value of stock warrants |
� |
� |
� |
� |
� |
273 |
� |
� |
� |
� |
� |
� |
(3,012 |
) |
||
|
Total other expense, net |
� |
� |
(893 |
) |
� |
� |
(933 |
) |
� |
� |
(2,897 |
) |
� |
� |
(6,554 |
) |
|
Net loss |
� |
$ |
(19,899 |
) |
� |
$ |
(13,061 |
) |
� |
$ |
(61,058 |
) |
� |
$ |
(39,525 |
) |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Net loss per share, basic and diluted |
� |
$ |
(0.85 |
) |
� |
$ |
(60.96 |
) |
� |
$ |
(2.64 |
) |
� |
$ |
(187.33 |
) |
|
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
� |
|
Weighted average shares used to compute basic and diluted �� net loss per share |
� |
� |
23,472 |
� |
� |
� |
214 |
� |
� |
� |
23,171 |
� |
� |
� |
211 |
� |
�
�
�
Media Contact:
Steve Sabicer
714-907-6264
Investor Contact:
Susan Morrison
858-366-6900 x7005